Photocure ASA · OSL:PHO
Photocure ASA — ABG Sundal Collier Virtual Oncology Seminar 2020
26 slides from Photocure ASA's conference presentation, Jun 10, 2020
Slide 1: Photocure ASA Company Presentation
PHOTOCURE ASA COMPANY PRESENTATION ABG SUNDAL COLLIER VIRTUAL ONCOLOGY SEMINAR 10 June 2020 Daniel Schneider, President and CEO
Slide 2: Disclaimer
DISCLAIMER By reading this company presentation (the “Presentation”), or attending any meeting or oral presentation held in relation thereto, you (the “Recipient”) agree to be bound by the following terms, conditions and limitations. The Presentation has been produced by Photocure (the “Company”) fo
Slide 3: Photocure at a Glance
PHOTOCURE AT A GLANCE Accelerating Oslo (HQ) revenue growth: +23% total sales NOK 1.6 billion Princeton (NJ) revenue growth in Market cap** 2019 Norwegian commercial-stage pharmaceutical NOK 330M global 585K Avg daily company focused on bladder cancer. in-market sales* volume YTD** Created in 1997 a
Slide 4: Our mission is to deliver transformative solutions for bladder cancer patients
OUR MISSION IS TO DELIVER TRANSFORMATIVE SOLUTIONS WHICH IMPROVE THE LIVES OF BLADDER CANCER PATIENTS Photocure’s four step strategy will deliver our mission 1 2 3 4 Accelerate Expand Acquire Transform • Drive the breadth •A Generate sales in • Partner and in- • Build a global and depth of new geogr
Slide 5: Large unmet needs in non-muscle invasive bladder cancer
LARGE UNMET NEEDS IN NON-MUSCLE INVASIVE BLADDER 9th 550,000 200,000 most common new cases1 deaths annually cancer worldwide1 of which 75% are men1 CANCER (NMIBC) COMMON #1 USD 5.7 Billion Highest per patient Cost of Bladder Cancer in the U.S., lifetime treatment costs projection for 20203 EXPENSIVE
Slide 6: The patient journey – characterized by long term follow-up with repeat procedures
THE PATIENT JOURNEY – CHARACTERIZED BY LONG TERM FOLLOW-UP WITH REPEAT PROCEDURES Outpatient & Clinic Diagnostic Cystoscopy Targeting flexible scope ~700k procedures Operating room EU/USA TURBT Targeting Rigid scope Symptoms ~1.6 mill procedures EU/USA Outpatient & Clinic Surveillance Cystoscopy fle
Slide 7: Hexvix/Cysview for better detection and management of NMIBC
HEXVIX®/CYSVIEW® FOR BETTER DETECTION AND MANAGEMENT OF NMIBC A Drug Device combination for better visual contrast between benign and malignant cells is taken up selectively Hexvix / Cysview is used by cancer cells in with a blue light enabled the bladder cystoscope, from Karl making them Storz, Wol
Slide 8: Blue light cystoscopy: creating a new standard of care
BLUE LIGHT CYSTOSCOPY: CREATING A NEW STANDARD OF CARE “YOU CANNOT TREAT WHAT YOU CANNOT SEE!” Risk that 20-35% of cancer patients will be missed, if Blue Light Cystoscopy is NOT used1,2 Risk of wrong risk-classification leading to mismanagement of disease, if Blue Light Cystoscopy is NOT used White
Slide 9: Positioned for growth
Positioned for growth
Slide 10: U.S. accelerated momentum: explosive & sustainable growth in the past 24 months
U.S. ACCELERATED MOMENTUM: EXPLOSIVE & SUSTAINABLE GROWTH IN THE PAST 24 MONTHS 98 704 63 807 42 607 30 465 23 017 12 278 8 249 4 921 2012 2013 2014 2015 2016 2017 2018 2019 U.S. (1000 NOK) 10
Slide 11: Recent quarters' installation fuels future growth
U.S. ACCELERATED MOMENTUM: RECENT 8 QUARTERS’ INSTALLATION FUELS FUTURE GROWTH! Annual New Installations Cumulative install base continues strong trend * * Tower placements by year 11 *2012 – 17 of the 23 installations were converted clinical sites upon Cysview approval
Slide 12: Hexvix/Cysview – key enablers in place and ready for growth
HEXVIX®/CYSVIEW® – KEY ENABLERS IN PLACE AND READY FOR GROWTH WE WILL GET THE 5 KEY ENABLERS IN PLACE FOR EU Penetration POSITION IN THE LIFE CYCLE KEY SUCCESS FACTORS 100% Approval Surgical & surveillance 75% Acceptance Major & local guidelines Denmark Permanent and 50% Access favorable reimburseme
Slide 13: Hexvix/Cysview future potential: therapeutic patent secured
HEXVIX®/CYSVIEW® FUTURE POTENTIAL: THERAPEUTIC PATENT SECURED Recent early stage studies show a potential treatment effect of Blue Light Cystoscopy (BLC™) with Hexvix1 Study results: a treatment effect could be related to – direct anti-tumor effect – immune cell activation Photocure has the intentio
Slide 14: Expand and Acquire World Wide Rights to Hexvix
Expand and Acquire World Wide Rights to Hexvix
Slide 15: Photocure unlocks tremendous potential in Europe
PHOTOCURE UNLOCKS TREMENDOUS POTENTIAL IN EUROPE Strategic opportunity Value-creation opportunity • Apply commercial success & strong growth in the • After transition year targeting approximately 30% annual Nordic and the U.S. markets to the European region revenue growth in European territories • D
Slide 16: Large untapped potential in the EUR 150 mill European market
LARGE UNTAPPED POTENTIAL IN THE EUR 150 MILL EUROPEAN MARKET (CURRENT EU PENETRATION (EXCEPT DACH) <5% WITH OPPORTUNITY TO REACH NORDIC LEVEL OF 40%) Europe U.S. Europe: 165,000 new US: 82,500 new cases NORDICS cases and more than and more than 18,000 40% penetration 50,000 deaths deaths annually1 a
Slide 17: IP Protection Strategy
IP Protection Strategy att
Slide 18: Drug-device combination – hurdles to market entry
DRUG-DEVICE COMBINATION ‒ HURDLES TO MARKET ENTRY NO PDT PRODUCTS HAVE EXPERIENCED GENERIC COMPETITION (VISUDYNE, METVIX) TO DATE 1 IP*/Intellectual Property 3 Technical/Manufacturing 4 Regulatory hurdles Review multiple patents, regulatory data hurdles A drug-device combination product. ANDA1 for p
Slide 19: Cevira License Agreement
Cevira® License Agreement
Slide 20: Cevira: license agreement with Asieris
CEVIRA®: License Agreement terms: LICENSE AGREEMENT WITH ASIERIS USD 250 mill potential in total: ASIERIS MEDITECH • Asieris is a subsidiary of the China-based Jiangsu Under the License Agreement, CO., Ltd. Yahong Meditech Co., Ltd., a specialty pharma Photocure has received a total signing company
Slide 21: Q1 2020 Financials
Q1 2020 Financials - ae
Slide 22: Financial performance - first quarter 2020
FINANCIAL PERFORMANCE - FIRST QUARTER 2020 CONTINUED U.S. GROWTH • U.S.: Strong revenue growth 33%. Growth in USD 21%, driven Amounts in NOK million Q1 ’20 Q1 ‘19 Change FY ‘19 by unit sales and price Commercial Franchise – Impact of Covid-19 on unit sales from last weeks of quarter US revenue 28.2
Slide 23: Summary and Outlook
Summary and Outlook — ——
Slide 24: Optimistic to rebound from COVID-19 impact in H2
OPTIMISTIC TO REBOUND FROM COVID-19 IMPACT IN H2 BLCTM with Hexvix®/Cysview® can play an integral part in this situation: postponed procedures* do not postpone aggressive cancer progression • Patient safety through better detection of bladder cancer tumors, in spite of the potential longer check-up
Slide 25: Creating the leading bladder cancer company
CREATING THE LEADING BLADDER CANCER COMPANY 1 2 3 4 Accelerate Expand Acquire Transform • Drive the breadth •A Generate sales in • Partner and in- • Build a global and depth of new geographies license synergistic Bladder Cancer Hexvix/Cysview assets to Company usage in key •B Enhance the value stren
Slide 26: Q&A
Q&A
Photocure — ABG Sundal Collier Virtual Oncology Seminar 2020 on 6ix